Mugurel Apetrii

Abstract Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney disease, characterized by progressive cyst growth and decline in renal function. Data on urinary biomarkers in ADPKD patients receiving disease-modifying therapy remain limited.

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

1 European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4–G5D. Osteoporosis is a substantial health concern worldwide, particularly among individuals with advanced chronic kidney disease (CKD). In this population, bone fragility is a prevalent complication attributable to disruptions in mineral and hormonal equilibria, leading to a non-vertebral-fracture risk that is 4 to 6 times higher than that of matched control individuals.